Ultragenyx Pharmaceutical Inc.

May 15, 2026 • Author: Phil Ratcliff

Item	Proposal	Vote
1a	Election of the three nominees for directors: Emil D. Kakkis, M.D., Ph.D.	Withhold(94.263)
1b	Election of the three nominees for directors: Shehnaaz Suliman, M.D.	✓ For(94.263)
1c	Election of the three nominees for directors: Daniel G. Welch	✓ For(94.263)
2	Approval of the Third Amended and Restated 2023 Incentive Plan.	✗ Against(94.263)
3	Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.	✓ For(94.263)
4	Advisory (non-binding) vote to approve the compensation of our named executive officers.	✓ For(94.263)

Attachments

📄

RARE_2025_10k.pdf 1.6 MB

📄

RARE_Proxy_Statement.pdf 3.0 MB

This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.